Evidence map›Paper›PMID 40844514›Full record

Observational studyAnnals of hematology2025

PNH clones prevalence study in ph-negative myeloproliferative neoplasms: a multicenter Italian study.

Alessandra D'Addio, Michela Rondoni, Marzia Salvucci, Giovanni Marconi, Massimiliano Bonifacio, Ilaria Tanasi, Omar Perbellini, Giuseppe Carli, Patrizia Tosi, Simona Tomassetti and 10 more

Abstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Alessandra D'AddioU.O.C. di Ematologia, Ospedale di Ravenna e Università di Bologna, Ravenna, Italy.
Michela RondoniU.O.C. di Ematologia, Ospedale di Ravenna e Università di Bologna, Ravenna, Italy.
Marzia SalvucciU.O.C. di Ematologia, Ospedale di Ravenna e Università di Bologna, Ravenna, Italy.
Giovanni MarconiU.O.C. di Ematologia, Ospedale di Ravenna e Università di Bologna, Ravenna, Italy.
Massimiliano BonifacioDepartment of Medicine, Section of Hematology, University of Verona, Verona, Italy.
Ilaria TanasiDepartment of Medicine, Section of Hematology, University of Verona, Verona, Italy.
Omar PerbelliniULSS8 Berica, Ospedale San Bortolo, Vicenza, Italy.
Giuseppe CarliULSS8 Berica, Ospedale San Bortolo, Vicenza, Italy.
Patrizia TosiU.O Ematologia, Azienda Unità Sanitaria Locale della Romagna, Rimini, Italy.
Simona TomassettiU.O Ematologia, Azienda Unità Sanitaria Locale della Romagna, Rimini, Italy.
Giovanni PolettiU.O. Patologia Clinica, Laboratorio Unico AUSL Romagna, Cesena, Italy.
Evita MassariU.O. Patologia Clinica, Laboratorio Unico AUSL Romagna, Cesena, Italy.
Marco RosettiU.O. Patologia Clinica, Laboratorio Unico AUSL Romagna, Cesena, Italy.
Elisabetta FabbriS.S. Ricerca Clinica e Organizzativa, AUSL della Romagna and IRCCS Meldola "Dino Amadori", Meldola, FC, Italy.
Chiara ZingarettiS.S. Ricerca Clinica e Organizzativa, AUSL della Romagna and IRCCS Meldola "Dino Amadori", Meldola, FC, Italy.
Alessandro LucchesiHematology Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, FC, Italy.
Maria Teresa BochicchioBiosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, FC, Italy.
Giorgia SimonettiBiosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, FC, Italy.
Mauro KramperaDepartment of Medicine, Section of Hematology, University of Verona, Verona, Italy.
Francesco LanzaU.O.C. di Ematologia, Ospedale di Ravenna e Università di Bologna, Ravenna, Italy. francesco.lanza@auslromagna.it.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The prevalence of paroxysmal nocturnal hemoglobinuria (PNH) clones is little investigated in myeloproliferative neoplasms (MPN) patients. The aim of this multicenter study was to evaluate the prevalence of PNH clones (glycosyl-phosphatidyl-inositol lacking) in 119 Ph- negative MPN patients having anemia, LDH elevation, asthenia and history of thrombosis. All the participating centers performed the standardized diagnostic test by using a single lyophilized template for granulocytes, monocytes, and erythrocytes. Next generation sequencing (NGS) was performed in 2 PNH-positive MPN cases and 13 PNH-negative MPN. The prevalence of PNH positive clones was 3.23% (n. 3 patients). All three patients had splenomegaly; none of them had thrombosis. One patient affected by CALR mutated essential thrombocytopenia, had a small clone (0.52%), clinically irrelevant; one patient affected by JAK2

Indexed as

Hemoglobinuria, ParoxysmalMyeloproliferative DisordersAdultAgedAged, 80 and overCalreticulinClone CellsFemaleHumansItalyJanus Kinase 2MaleMiddle AgedMutationPrevalenceCalreticulinJanus Kinase 2Cal-RFlow cytometryGenetic lesionsMyeloproliferative neoplasmsNGSParoxysmal nocturnal hemoglobinuria clone

Identifiers

PMID40844514
PMCPMC12552278

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.